[December 19, 2014] |
|
Research and Markets: Autism - Pipeline Review, H2 2014
Research and Markets (http://www.researchandmarkets.com/research/xhmrlm/autism_pipeline)
has announced the addition of the "Autism
- Pipeline Review, H2 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Autism, complete with comparative analysis at various
stages, therapeutics assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type, along with
latest updates, and featured news and press releases. It also reviews
key players involved in the therapeutic development for Autism and
special features on late-stage and discontinued projects.
Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinical trials registries tracking ensure tht the most recent
developments are captured on a real time basis.
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Autism
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Autism pipeline depth and focus of Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
F. Hoffmann-La Roche
-
Sumitomo Dainippon Pharma
-
Egenix
-
Novartis
-
Merz Pharma GmbH & Co
-
Mitsubishi (News - Alert) Tanabe Pharma Corporation
-
Teva Pharmaceutical Industries
-
BrainStorm Cell Therapeutics
-
Avanir Pharmaceuticals
-
Curemark
-
Coronado Biosciences
-
Omeros Corporation
-
Intra-Cellular Therapies
-
Cellceutix Corporation
-
Heptares Therapeutics
-
Edison Pharmaceuticals
-
Otsuka Holdings
-
Reviva Pharmaceuticals
-
Naurex
-
Mnemosyne Pharmaceuticals
-
BioCrea
-
Saniona
-
Confluence Pharmaceuticals
-
MedDay
For more information visit http://www.researchandmarkets.com/research/xhmrlm/autism_pipeline
[ Back To TMCnet.com's Homepage ]
|